From: oncnet.com Proton radiotherapy is an effective and safe alternative to conventional radiotherapy, according to results from a phase 2 study of patients with nonmetastatic breast cancer (J Clin Oncol. 2019 Aug 26. Epub ahead of print). Rachel Jiminez, MD, Massachusetts General Hospital, Boston, MA, and colleagues, conducted the phase 2 study with aims to evaluate the safety and efficacy of …
Context Therapeutics and SOLTI launch ONAWA: a Window of Opportunity Study in Breast Cancer with Apristor
Source: Business Wire From: manchestertimes.com Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing medicines for hormone driven cancers, today announced a clinical collaboration with SOLTI, a leading collaborative and academic group in Spain dedicated to clinical and translational research in breast cancer. This clinical collaboration, being supported by Context and sponsored by SOLTI, is a window of opportunity study …
Newly Approved Targeted Therapy Paves the Way for Patients With Advanced Bladder Cancer
By: Katie Kosko From: curetoday.com Patients with advanced bladder cancer and a specific gene mutation have a promising new treatment option, according to phase 2 study findings published in the New England Journal of Medicine. The international trial was led by researchers from The University of Texas MD Anderson Cancer Center and included 99 patients with metastatic urothelial carcinoma or …
Oncologie, Inc. Announces Clinical Trial Collaboration With Merck to Evaluate Bavituximab in Combination With KEYTRUDA® (Pembrolizumab) in Advanced Gastric or Gastroesophageal Cancer
From: PR Newswire Oncologie, Inc., a clinical-stage biopharmaceutical company developing innovative oncology treatments targeting the tumor microenvironment, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate the combination of Oncologie’s investigational drug Bavituximab, an antibody that blocks the activity of phosphatidylserine (PS), and Merck’s anti-PD-1 therapy, …
Upcoming Phase 2 Trial Will Test Opdivo-MTG201 Combo for Malignant Pleural Mesothelioma
By: Patricia Inacio, PhD From: immuno-oncologynews.com An upcoming Phase 2 trial will explore the safety and effectiveness of a combo therapy — Opdivo (nivolumab) and MTG201 – for the treatment of malignant pleural mesothelioma. The trial will soon be looking for participants who received prior chemotherapy. Mesothelioma is a rare type of cancer, commonly linked to exposure to asbestos, that …
GeneCentric and Collaborators at Washington University Advance Academic-Industry Head and Neck Cancer Partnership under NCI Grant
Source: GeneCentric Therapeutics, Inc. From: biospace.com GeneCentric Therapeutics, Inc. today announced that it has entered the second phase of an academic-industry collaboration with Jose Zevallos MD, MPH, Chief of the Division of Head and Neck Oncologic Surgery in the Department of Otolaryngology at Washington University School of Medicine in St. Louis. This collaboration is funded by a National Cancer Institute …
Amgen Plans Pivotal Lung Cancer Trial For Its Pipeline Star
Source: Andrew Dunn, BiotechDive From: pharmavoice.com Amgen stole the show at this year’s annual meeting of the American Society of Clinical Oncology with promising early data from a cancer drug designed to target KRAS mutations, an elusive target that’s frustrated decades of research efforts. Now, the biotech plans to soon advance the drug into a Phase 2 study in lung …
First-in-Class Drug Preserves Blood Counts During Chemotherapy for Lung Cancer
By: Beth Fand Incollingo From: curetoday.com Given with each dose of chemotherapy, administration of trilaciclib may temporarily put bone marrow to sleep, helping to prevent fevers, infections and hospital stays in patients with small cell lung cancer, according to study findings presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Side effects from chemotherapy often include nausea, …
G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy
Source: G1 Therapeutics From: globenewswire.com G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from a randomized Phase 2 trial which demonstrated that women with metastatic triple-negative breast cancer (mTNBC) lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone. Detailed data from this trial will be presented at …
Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Source: Business Wire From: apnews.comrec Seattle Genetics, Inc. (Nasdaq:SGEN) today announced completion of enrollment in the potentially pivotal innovaTV 204 phase 2 clinical trial evaluating the efficacy, safety and tolerability of tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment. Tisotumab vedotin is being developed in collaboration …
- Page 1 of 2
- 1
- 2